Review
Version 1
Preserved in Portico This version is not peer-reviewed
Phosphodiesterase 4 Inhibition in the Management of Psoriasis
Version 1
: Received: 3 November 2023 / Approved: 3 November 2023 / Online: 6 November 2023 (07:07:05 CET)
A peer-reviewed article of this Preprint also exists.
Crowley, E.L.; Gooderham, M.J. Phosphodiesterase-4 Inhibition in the Management of Psoriasis. Pharmaceutics 2024, 16, 23. Crowley, E.L.; Gooderham, M.J. Phosphodiesterase-4 Inhibition in the Management of Psoriasis. Pharmaceutics 2024, 16, 23.
Abstract
Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatment options for psoriasis, phosphodiesterase-4 (PDE4) inhibi-tors are emerging with expanding options. PDE4 inhibitors play a pivotal role in the inflamma-tory cascade by degrading cyclic adenosine monophosphate (cAMP), contributing to pro-inflammatory mediator production. Apremilast, an oral PDE4 inhibitor, is an approved class for psoriasis. While effective, its adverse effects can limit its utility. Roflumilast, a topical PDE4 inhibitor, was recently also approved for psoriasis and shows promise in clinical trials. Crisaborole, approved for atopic dermatitis, has also been studied in psoriasis. This updated re-view summarizes evidence from randomized clinical trials regarding the efficacy and safety of PDE4 inhibitors in psoriasis treatment. By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis therapy.
Keywords
psoriasis; PDE4 inhibitor; apremilast; roflumilast; crisaborole; clinical trials; review
Subject
Medicine and Pharmacology, Dermatology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
